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Abstract: Over the past two decades, developing medical 
applications for peptides has, and continues to be a highly 
active area of research. At present there are over 60 peptide-
based drugs on the market and more than 140 in various 
stages of clinical trials. The interest in peptide-based 
therapeutics arises from their biocompatibility and their ability 
to form defined secondary and tertiary structures, resulting in 
a high selectivity for complex targets. However, there are 
significant challenges associated with the development of 
peptide-based therapeutics, namely peptides are readily 
metabolised in vivo. Peptoids are an emerging class of 
peptidomimetic and they offer an alternative to peptides. 
Peptoids are comprised of N-substituted glycines where side-
chains are located on the nitrogen atom of the amide 
backbone rather than the α-carbon as is the case in peptides. 
This change in structure confers a high degree of resistance 
to proteolytic degradation but the absence of any backbone 
hydrogen bonding means that peptoids exhibit a high degree 
of conformational flexibility. Cyclisation has been explored as 
one possible route to rigidify peptoid structures, making them 
more selective, and, therefore more desirable as potential 
therapeutics. This review outlines the various strategies that 
have been developed over the last decade to access new 
types of macrocyclic peptoids.  
 
1. Introduction 
1.1. Peptide Drugs 
Research focused on the development of peptide-based 
drugs continues to gather momentum, in part due to the 
“chemical space” that peptides occupy between small 
molecules and biologics (e.g. antibodies). In addition 
properties such as biocompatibility and diversity, both in 
terms of functionality and structure, make them attractive 
candidates for a variety of biomedical and therapeutic 
applications. For example, some peptides (e.g. Nisin A) have 
been found to be highly active against Gram-positive and 
Gram-negative bacteria[1]  while also appearing  to be less 
susceptible to bacterial resistance than conventional 
antibiotics.[2] The versatility in the structure and functionality 
of peptides enables them to bind specifically to cell receptors, 
for example, G protein-coupled receptors (GPCRs), which are 
responsible for triggering cell signalling responses.[3] This 
raises the possibility of using peptides to selectively treat 
metabolic diseases and different types of cancers,[4] as well 
as offering the chance to exploit their targeting properties in 
areas such as drug delivery[5] and cellular imaging.[6] 
Accordingly, there are over 60 peptide drugs currently 
approved by the US Food and Drug Administration (FDA), 
and more than 140 in different stages of clinical trials.[4] 
However, despite the promise that peptides offer as 
therapeutic agents, there are significant obstacles to 
overcome in terms of their development as commercially 
viable drugs. In particular peptides may often show a high 
level of activity in vitro but be completely ineffective in vivo 
due to rapid degradation by proteases.[7] A short in vivo half-
life also means that for peptides oral administration is very 
rarely possible, thus further limiting their utility as drugs. To 
overcome these barriers, molecules resembling peptides are 
being developed by many groups in both academia and 
industry. These molecules are often referred to as 
peptidomimetics and among these are a class of compounds 
known as peptoids (Figure 1).[8]  
 
 
Figure 1. A structural comparison of α-peptides and α-peptoids.  
1.2. Peptoids 
Whilst peptoids do share some similarities with peptides, 
such as biocompatibility and the ability to incorporate different 
functional groups via their side-chains, they have significant 
differences. The side-chains within a peptoid are moved from 
the α-carbon to the amide nitrogen. This structural change 
means that a peptoid backbone is made up from repeating 
tertiary amides which imparts an extreme resistance to 
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enzymatic degradation. Furthermore, the shift of the side-
chain means there are no stereogenic centres on the peptoid 
backbone. The lack of amide backbone protons means that 
peptoids are more flexible than their peptide counterparts as 
it is the inter- and intra-chain hydrogen bonding involving the 
amide proton in peptides that enables the formation of α-
helices, β-sheets etc. The backbone tertiary amides within 
peptoids are able to adopt cis- or trans-conformations and 
any stable secondary structures are derived purely from steric 
and/or electronic interactions.[9] This means that peptoids are 
not as readily denatured by solvent and temperature changes 
as their peptide counterparts. [10] Peptoids are routinely 
synthesised using the highly flexible sub-monomer method 
developed by Zuckermann et al. (Scheme 1). This is a solid 
phase synthesis approach, which comprises two steps: 
acylation using a halo-acetic acid (typically bromoacetic acid), 
then displacement using a primary amine.[9a] There are other, 
less commonly used methods of peptoid synthesis, for 
example, solid phase monomer synthesis,[11] and solution 
phase methods such as ring-opening polymerisation of N-
substituted N-carboxyanhydride monomers[12] and Ugi 4-
component reactions,[13] but these are beyond the scope of 
this review, except for when specific examples have played a 
key role in accessing macrocyclic peptoids. 
 
 
Scheme 1. The sub-monomer method for peptoid synthesis.  
1.3. Cyclic Peptoids 
In order to design drugs that interact with a specific target, 
conformational rigidity is important. As well as increasing the 
affinity of the compound to the target,[14] conformational 
rigidity reduces the likelihood of any off-target effects that 
may be due to a lack of specificity.[15] Limiting off-target 
effects is particularly difficult whilst treating certain diseases; 
the side-effects that commonly occur during current cancer 
treatments are well documented.[16] In nature, one of the ways 
in which conformational rigidity is achieved is by forming 
covalent bonds that effectively ‘staple’ the three-dimensional 
structure of the peptide in place. For example, nature 
produces numerous cyclic peptides that exhibit a range of 
potent biological activities including antibacterial properties.[17] 
In many classes of peptides di-sulphide bridges (between 
cysteine residues) are commonly used to constrain peptide 
conformation, and also enhance stability towards 
degradation.[18] Taking inspiration from nature, researchers 
have reported a wide range of synthetic peptides, where 
cyclisation was used as a strategy to enhance resistance to 
proteolysis and also effect greater cell penetration.[19] 
In linear peptoids the main source of conformational 
heterogeneity arises due to cis- trans-isomerisation around 
the backbone amide bond.[20] In an effort to access stable 
peptoid structures there has been increasing interest in new 
routes to access cyclic peptoids.[21] As with peptides, cyclic 
peptoids have been shown in several cases to improve cell 
penetration and also to enhance antimicrobial activity when 
compared to their linear precursors.[22] Cyclisation of linear 
peptoids restricts the movement of the amide backbone, 
increasing rigidity and reducing the number of possible 
conformations. Cyclic peptoids were first reported in 2007 by 
the Kirshenbaum group, and an excellent review by Yoo et al. 
(published in 2010) summarised the initial work carried out 
within the field to make peptoid macrocycles.[23] This current 
review provides an update on the progress within the field 
and it focusses on the work carried out from 2010 onwards. 
The cyclisation strategies have been collated into three 
general categories: head-to-tail, side chain-to-side chain and 
side chain-to-tail cyclisation and these are discussed in the 
context of their possible applications.  
2. Head-to-Tail Cyclisation 
Cyclic peptoid structures have been reported since at least 
1969,[24] however, they were not labelled as such; indeed the 
term “peptoid” was only coined in the late 1980s[25] and so the 
first major report of the synthesis of peptoid macrocycles is 
considered to be the 2007 paper by the Kirschenbaum 
group.[19a] The approach used a head-to-tail cyclisation 
strategy. Ring formation was carried out in the solution phase 
as a condensation reaction between the N-terminus and the 
C-terminus of the linear peptoid precursor (Scheme 2, where 
1 was prepared by cleavage from 2-chlorotrityl resin).   
 
 
Scheme 2. Formation of a peptoid macrocycle (2) via head-to-tail 
cyclisation of a linear peptoid hexamer (1).  
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Linear peptoid chains up to 20 monomers in length 
underwent rapid room temperature head-to-tail cyclisations 
giving up to 90% yields after 5 minutes and at moderate 
dilutions (0.6 – 3.0 mM). Cyclisation of the peptoid octamer 
[(NpheNme)4] at concentrations ranging from 0.3 to 78 mM 
was found to proceed with little accumulation of the unwanted 
dimeric product formed though intermolecular reaction. 
Conversely, increased ring strain meant that the tetramer 
[(NpheNme)2] only cyclised with a 12% yield after 5 minutes. 
Notably, Shin et al. managed to crystallise the cyclic hexamer 
(2) and the resulting crystal structure showed that the 
hydrophobic phenyl side-chains (Nphe) oriented on one face 
of the ring and the hydrophilic methoxy ethyl side-chains 
(Nme) oriented on the other face. This has implications for 
the future design of high order peptoid oligomers; it may be 
possible to design more complex peptoids which cyclise to 
form an ordered, amphiphilic structure.[19a]  
This method of head-to-tail cyclisation was used in 2013 
by the Kirshenbaum group to make a cyclic peptoid octamer 
(4, Scheme 3) which assembles to form a nanotubular 
structure capable of reversibly sequestering water.[26] The 
linear parent peptoid (3) was designed to incorporate side-
chains that would impose a sequence of cis (c) and trans (t) 
amide bond configurations corresponding to ccttcctt; a 
sequence observed in many peptoid macrocycles.[19a] N-aryl 
glycine (Nph) monomer units have been shown to exhibit a 
strong preference for a trans-conformation, whilst some N-
alkyl (e.g. Npfe) monomer units show a preference for cis 
conformation (Figure 2).[27]  
 
 
 
 
 
 
Figure 2. N-aryl glycine (Nph) side-chain and pentafluorobenzyl (Npfe) 
side-chain which favour trans and cis conformations respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Formation of a cyclic peptoid (4) which assembles into a 
nanotubular structure and is capable of reversibly sequestering water. 
 
This principle was used to select the monomers in the 
synthesis of the linear parent peptoid (3); the aryl groups 
(Nph) enforced the trans-conformation about the amide 
bonds whilst the methoxy groups (Nme) were included to 
improve water solubility and the propargyl groups (Nprp) 
allowed for possible further modification. The crystal structure 
of the resulting macrocyclic peptoid (4) had a conformation 
that was as predicted, with the alkyl groups allowing a cis-
conformation of associated amide bonds and the aryl groups 
enforcing trans-conformations (Figure 3).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Crystal structure of water-sequestering peptoid macrocycle: (4), 
a) crystal structure of single molecule with oxygen in red and, nitrogen in 
blue and hydrogen in white; b) top view of three stacked peptoid 
macrocycles showing the cavity in which water (red) is sequestered; c) 
side view of three stacked peptoid macrocycles. Hydrogen is omitted 
(except for the water molecules) for clarity.  
Cyclic peptoid hexamers based on Kirshenbaum’s scaffolds 
have been found to exhibit various interesting properties, 
including antimicrobial action.[21, 22, 28] The De Riccardis group 
have contributed significantly to this area, highlighting the 
potential of these cyclic peptoid motifs to take up guest 
molecules,[29a] to act as phase-transfer catalysts,[29b] to 
complex metals, including gadolinium, [29c]  and to act as 
glycosidase inhibitors via formation of iminosugar-
cyclopeptoid conjugates. [29d,e] De Riccardis and co-workers 
have also recently carried out elegant detailed studies on the 
conformational isomerism that occurs in cyclic peptoids of this 
type.[29f]  
2.1. Small Head-to-Tail Macrocyclic α-Peptoids 
Since 2007, efforts have been underway to synthesise 
smaller (3- to 5- mer) cyclic peptoids, but the yields obtained 
were often relatively low , particularly for the trimers(< 20%) 
or conditions were not optimised.[21, 30] Accessing this type of 
peptoid is desirable given that small cyclic tetra-peptides 
have been shown to act as histone deacetylase inhibitors 
(HDIs).[31] HDIs have long been used as mood stabilisers and 
anti-epileptics, but are now also attracting interest as possible 
treatments for inflammatory[32] and parasitic diseases,[33] as 
well as cancers.[34] In 2012, Olsen et al. reported the 
synthesis of cyclotetrameric peptoid-peptide hybrids which 
inhibited class 1 histone deacetylases.[35] Hoping to provide 
the tools to eventually make entirely peptoid-based HDIs, in 
2014, Culf et al. optimised conditions for the synthesis of 
a) 
b) 
c) 
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cyclic tri-, tetra- and penta-peptoids (Scheme 4) and were 
able to access yields of 80 – 97%.[36]  
The reactions were carried out in solution using a 
variety of activators and bases and it was found that a 
mixture of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC), 1-Hydroxy-7-azabenzotriazole (HOAt) and 
trimethylamine (TEA) resulted in the best yields. When n = 1 
or 3 the reported yields after overnight, room temperature 
incubation were 90% and 97% respectively (Scheme 4). 
Under the same conditions, when n = 2, the reported yield 
was 38%, but when EDC and TEA were replaced with 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU) and 
diisopropyl ethylamine (DIPEA), and the reaction was carried 
out at 50oC overnight, the reported yield rose to 80%. The 
authors did not elaborate on why the cyclisation of n = 2 was 
such a challenge, however they speculated that an increase 
in temperature improved the yield because of an increased 
rate of cis-trans isomerisation about the amide bonds.  
 
 
Scheme 4. Head-to-tail cyclisation of short linear peptoids (5) to form small 
cyclic peptoids (6). 
In 2013, Caumes et al. published work investigating the effect 
of the nature of the side-chains in the cyclisation of α,β-
tetrapeptoids. They found that the presence of at least one N-
Cα-branched side-chain was critical for successful cyclisation 
of these peptoids. Attempts to make cyclic α,β-tetrapeptoids 
bearing four propargyl side chains was unsuccessful under 
almost all conditions attempted, with the most successful 
attempt resulting in a <10% yield of the desired cyclic peptoid, 
and significant amounts (>20% yield) of the dimeric form. 
However, when one of these propargyl groups was replaced 
by an Nspe monomer, cyclisation occurred. The group was 
able to obtain a crystal structure of an α,β-cyclic tetrapeptoid 
with alternating Nspe  (on the β-peptoid) and propargyl (on 
the α-peptoid) side chains (7). The crystal structure showed 
that the peptoid adopted a βcis-αtrans-βcis-α-trans 
configuration (Figure 4).[37] 
 
 
 
 
 
 
 
Figure 4. α,β-cyclic tetrapeptoid (7) made by Caumes et al. a) Chemical 
structure showing alternating Nspe and propargylglycine monomers; b) 
crystal structure of 7 showing a ctct backbone geometry. Hydrogen is 
omitted for clarity.   
2.2. Macrocyclic Arylopeptoids 
An interesting variation of the head-to-tail cyclisation 
approach was reported in 2014 by Hjelmgaard et al. where 
arylopeptoids were cyclised and found to form higher order 
nano-tubular structures.[38] Arylopeptoids, which are 
considered to be a subclass of peptoids whereby the 
backbone is extended by a phenyl ring at each residue, are 
closely related to N-alkylated para-cyclophanamides (Figure 
5). Macrocyclic N-alkylated para-cyclophanamides, if the R 
group is a long, hydrophobic chain, form a hydrophobic cavity 
and thus, these compounds show potential as selective hosts 
and artificial enzymes. Arylopeptoids can be efficiently 
synthesised, using the sub-monomer method, and can readily 
undergo head-to-tail macrocyclisation (Scheme 5) to form 
rigid, well-defined structures, similar to N-alkylated para-
cyclophanamides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Comparison of the repeating units of N-alkylated para-
cyclophanamides and arylopeptoids. 
The reactions in Scheme 5 were carried out on ortho-, meta- 
and para-arylopeptoids. Para-arylopeptoids have a rigid 
backbone which means that head-to-tail cyclisation is 
challenging. Thus the resulting macrocycles were 
cyclohexamers (n=4, e.g. 8) rather than cyclotrimers (n=1). 
Formation of the cyclotrimer (9) or cyclohexamer (10) from 
the ortho-arylopeptoid is dependent on the nature of the side-
chain; the substituents around the ring are more hindered, so 
a bulky side-chain will favour formation of the cyclohexamer. 
Conversely, the meta-arylopeptoid favours the cyclotrimer 
(11), even with a bulky isopropyl side-chain.  
 
 
 
 
Scheme 5. Head-to-tail macrocyclisation of arylopeptoids. 
a) b) 
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Figure 6. Crystal structure of orthoarylopeptoid cyclohexamer (10): a) 
crystal structure of single molecule with oxygen in red and, nitrogen in blue 
and hydrogen in white; b) top view of three stacked arylopeptoid 
macrocycles showing the cavity containing water (red) and acetonitrile 
(yellow); c) side view of three stacked peptoid macrocycles. Hydrogen is 
omitted (except for the water and acetonitrile molecules) for clarity. 
 X-ray crystallographic analysis of these peptoid macrocycles 
showed the formation of higher order tubular structures. In 
the case of the ortho-arylopeptoid, when the side-chains are 
isopropyl groups, the cyclohexamer (10) which is formed 
contains one acetonitrile molecule (from the crystallisation 
solvent) in an interior cavity (Figure 6). The cyclohexamers 
(10) were found to stack to form a tubular array, even in the 
absence of any hydrogen bonding. It was speculated that a 
water molecule which bridges two consecutive rings may 
stabilise the supramolecular assembly. Importantly, the 
presence of the acetonitrile molecule indicates that the 
interior cavity of this tubular array is large enough to 
accommodate a guest molecule, and thus the system has the 
potential to be developed into a selective host. 
 
2.3 Macrocyclic Benzylopeptoids 
 
Closely related to arylopeptoids are benzylopeptoids 
(Scheme 6). 
 
 
 
 
 
 
 
  
Scheme 6. Cyclisation of benzylopeptoids . 
Cyclisation was carried out under similar conditions to those 
used to cyclise the arylopeptoids (Scheme 5 for the 
arylopeptoids and Scheme 6 for the benzylopeptoids). A 
solution of the linear benzylopeptoid was added to a solution 
of HATU and DIPEA in DMF over 6 hours at room 
temperature and left at room temperature for a further 18 
hours. Cyclic ortho-, meta- and para-benzylo tri- and tetra 
peptoids were successfully synthesised in 26 – 72% yields 
with the para-benzylopeptoid proving most difficult to cyclise 
for both chain lengths. Subsequent NMR studies showed the 
ability of all six cyclic benzylopeptoids to complex with Na+ 
ions.[39] 
2.4 Consecutive Ugi Reactions  
The Ugi 4-component reaction (U-4CR) is a multi-component 
reaction (MCR) which involves a ketone or aldehyde, an 
isocyanide and a carboxylic acid (Scheme 7).[40] 
 
 
Scheme 7. General example of the Ugi 4-component reaction. 
The U-4CR is used to synthesise large libraries of 
compounds, thanks to the ready availability of a wide range of 
suitable building blocks. Whilst there are many reports of U-
4CRs being used to make linear peptoids and peptoid 
hybrids,[13a, 13d, 41] U-4CRs have also been used to make and 
cyclise peptoids.  
In 2008, Vercillo et al. reported the syntheses of peptoid 
macrocycles using consecutive U-4CRs as a way to generate 
peptoid-RGD motifs.[42] The peptide-RGD is the tripeptide L-
arginine-glycine-L-aspartate and peptoid-RGD is the 
corresponding peptoid sequence (i.e. with the side-chains 
moved from the α-carbons to the backbone amide nitrogen 
atoms). RGD is common to many peptides involved in cellular 
recognition[43] and the RGD loop is recognised by nearly half 
of all known integrins. Integrins are a family of cell-adhesion 
molecules and have key roles in various processes, including 
a) 
b) 
c) 
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thrombosis, metastasis and osteoporosis.[43] Hence, integrins 
are attractive therapeutic targets and Vercillo et al. hoped that 
their peptoid-RGD-containing macrocycles could be used in 
this way. 
In order to achieve this, three consecutive Ugi reactions 
were carried out; the first two, U-4CRs, yielded the acyclic 
parent peptoid (17) and the third, an Ugi three-component 4-
centre reaction, gave the macrocyclic peptoid 18 (Scheme 
8).[42]  
Many RGD peptide macrocycles and non-peptidic 
mimics have been shown to be highly active antagonists for a 
range of integrins.[44] These RGD peptide macrocycles and 
non-peptidic mimics are also selective for particular integrins, 
due to the conformational rigidity imposed by cyclisation. 
Unfortunately, studies on the activity and selectivity of 18 
were not reported and as such comparison with the 
macrocyclic peptide analogues is not possible.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8. Synthesis of peptoid-RGD-containing macrocycle (18) by 
consecutive Ugi reactions. 
3. Side-Chain Cyclisation 
3.1. Grubbs Ring-Closing Metathesis  
 
 
 
Figure 7. Representative Ring-Closing Metathesis (RCM). 
Olefin metathesis is a widely applied method of carbon-
carbon bond formation using ruthenium alkylidene catalysts. 
Ring-Closing Metathesis (RCM, Figure 7) can be used to 
form large macrocycles.[45] RCM has many features that 
make it attractive for use in the formation of cyclic peptoids; 
the catalysts are tolerant of a wide variety of functional 
groups, allowing variation in the side-chain groups. The 
catalysts are easily handled, not requiring the use of glove 
boxes, and the reaction is clean, producing few by-products, 
making purification straightforward. In general when transition 
metal catalysts are used in peptide or peptoid synthesis, solid 
phase approaches are preferred. This is because carrying out 
the reaction with the substrate on resin allows a much easier 
removal of any by-products including the transition metal. The 
solid phase synthesis of cyclic peptoids by RCM (Scheme 9) 
was first reported by Khan et al. in 2011.[46] 
Initially, the double bonds in the side-chain were 
incorporated through the use of allylamine in the substitution 
step of sub-monomer peptoid synthesis. This approach 
however, only produced the corresponding macrocyclic 
peptoids in very low yields (10 – 20%).[46] The linear parent 
peptoid was subsequently altered to extend the length of the 
alkene-containing side-chain by swapping allylamine for 3-
buten-1-amine. Various RCM catalysts were also screened, 
and the most effective one was found to be 19. This 
combination of longer side-chains and catalyst 19 produced 
the target macrocyclic peptoid in 80% yield. The reaction was 
carried out both under microwave conditions and at 40 oC on 
a shaker, with the latter conditions being slightly more 
efficient, particularly in minimising formation of unwanted 
dimers.  
 
 
 
 
Scheme 9. General approach utilised by Khan et al. for the formation of 
cyclic peptoids using an on resin Ring Closing Metathesis (RCM) strategy.  
 
3.2. Thiol-ene  
The thiol-ene reaction (Scheme 10) is considered a type of 
‘click chemistry’ due to its high yields, stereo-selectivity and 
fast reaction rates.[47] There are two mechanisms by which 
the thiol-ene reaction may proceed; either by radical addition 
or Michael addition, catalysed by either a base or a 
nucleophile. 
 
 
 
 
Scheme 10.  The thiol-ene reaction. 
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Scheme 11. Protection of maleimides by Diels-Alder reaction with 2,5-
dimethylfuran. 
The thiol-ene reaction has been used to cyclise peptides, 
using a maleimide (20) as the source of the double bond.[48] 
Non-protected maleimides can only be incorporated at the 
end of the chain since they are labile to the nucleophilic 
bases that are used in peptide/peptoid synthesis. 2,5-
Dimethylfuran (21) can be used to protect maleimides 
(Scheme 11); 2,5-dimethylfuran (21) reacts with the 
maleimide (20) by Diels-Alder cycloaddition. The protected 
maleimide (22) can then be deprotected by simply heating. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12. Peptoid cyclisation using the thiol-ene reaction. 
In principle, protection of the maleimide in this way 
allows it to be incorporated at any place in a peptide/peptoid 
chain; however, in the report by Elduque et al., maleimido 
group inclusion was at the N-terminus only (23). After 
cleavage from the resin, the maleimido group was 
deprotected and cyclisation occurred in the same step to give 
cyclic peptoid 24 (Scheme 12). In the same paper the 
cyclised peptoid (24) was modified with a nucleoside via 
Huisgen reaction between the alkyne side-chain and 2’,3’-
dideoxy-3’-azidothymidine (AZT, 25) (Scheme 13).[48] AZT 
(25) is an anti-retroviral drug used to treat HIV/AIDS.[49] At 
high doses, AZT is associated with side effects such as 
anaemia, neutropenia, hepatotoxicity, cardiomyopathy and 
myopathy. This limits the dose that can be given to patients, 
and this means that some HIV replication still occurs. This 
allows resistance to develop so that, ultimately, the 
progression of the disease is only slowed.[50] Development of 
resistance is slowed by combining AZT with other anti-
retroviral medicines. Conjugation of AZT to cyclic peptoids is 
of interest to see whether cell uptake and subsequent 
interaction with components of the cell is improved, or 
different.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 13. Conjugation of a nucleoside to a cyclic peptoid by Huisgen 
condensation to form an AZT-containing cyclic peptoid (26). 
3.3. Copper(I)-Catalysed Azide-Alkyne Cycloaddition 
(CuAAC) 
Copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) 
refers to a 1,3 dipolar cycloaddition between an azide and an 
alkyne to give a 1,2,3-triazole (Scheme 14). CuAAC is 
considered a ‘click’ reaction, and is catalysed by a Cu(I) 
compound in the presence of a non-nucleophilic base.[51] It is 
a high yielding and versatile reaction since the required 
functional groups are easily incorporated into a variety of 
compounds. 
 
Scheme 14. Copper(I)-catalysed azide-alkyne cycloaddition (CuAAC). 
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Scheme 15. CuAAC to form a cyclic peptoid. 
CuAAC as a method to cyclise peptoids was first reported in 
2007 by the Kirshenbaum group (Scheme 15).[52] This on-
resin reaction was used as a way to ‘staple’ helical peptoid 
chains in order to rigidify the structure. This approach was 
reviewed extensively in the 2010,[53] and will not be covered in 
detail here. However, in 2012, the Kirshenbaum group used 
CuAAC in the solution phase to form a novel bicyclic peptoid 
scaffold (Scheme 16).[53] 
A linear peptoid containing both azide and alkyne 
groups within the monomer side-chains (27) was first 
synthesised, cleaved from the resin and then cyclised by 
head-to-tail condensation between the N-terminus and the 
carboxylic acid-terminus to form the monocyclic peptoid (28). 
Bicyclic peptoid 29 was then formed by CuAAC between the 
side-chain alkyne and azide groups. This intramolecular 
reaction was the major reaction pathway under dilute 
conditions, giving a yield of 27% but formation of the 
homodimeric, doubly crosslinked peptoid (30) with a yield of 
4% was also observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Crystal structures of bicyclic peptoid cyclooctamer (29) and the 
homodimeric, doubly crosslinked peptoid (30): a) crystal structure of 
cyclooctamer (29) with oxygen in red and, nitrogen in blue and hydrogen in 
white; b) crystal structure of 29 highlighting the triazole and bridging side-
chains (purple) and the original cyclic peptoid structure obtained via head-
to-tail macrocyclisation (green); c) crystal structure of the homodimeric, 
doubly crosslinked peptoid (30) with oxygen in red and, nitrogen in blue 
and hydrogen in white; b) crystal structure of 30 highlighting the triazole 
and bridging side-chains (purple) and the original cyclic peptoid structures 
obtained via head-to-tail macrocyclisation (green). Non-bridging side-
chains and all hydrogen atoms are omitted for clarity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 16. Formation of a bicyclic peptoid (29, major product) using 
CuAAC, and the homodimeric, doubly crosslinked peptoid (30, minor 
product). 
a) b) 
c) d) 
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Crystal structures of 29 and 30 were obtained (Figure 
8). Whilst 30 appeared to exist in only one configuration, 
bicyclic peptoid 29 was found to be a mixture of two 
backbone conformations and further investigation determined 
the conformation of the monocyclic peptoid to be the main 
factor contributing to the conformation of the resulting bicyclic 
peptoid. The formation of bicyclic peptoids through the use of 
two different cyclisation approaches has not yet been widely 
exploited but it has the potential to unlock more complex, 
constrained peptoid conformations.  
4. Side Chain-to-Tail Cyclisation 
4.1 Triazine-Bridged Cyclic Peptoid-Peptide Hybrids 
In 2010, Lee et al. synthesised a library of sequencable cyclic 
peptoid-peptide hybrids of 3 to 10 residues and later used a 
similar approach to synthesise an anticancer cyclic peptoid-
peptide hybrid.[54] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 17. Cyclisation of a cysteine-containing peptoid-peptide hybrid. 
 
 The systems were designed to allow sequencing of hit 
compounds from high-throughput screening methods, such 
as one-bead-one-compound (OBOC). Linear peptoid-peptide 
hybrids were made containing a cysteine residue, and 
capped at the end with cyanuric chloride. Cyclisation was 
carried out in the presence of DIPEA overnight at room 
temperature (Scheme 17). The ring could then be opened by 
incubating the resin-bound material with mCPBA and NaOH 
overnight at room temperature to yield a linear peptoid-
peptide hybrid that, on cleavage from the resin, could be 
sequenced by tandem mass spec (MS/MS). The efficiency of 
the cyclisation reactions was investigated by analytical HPLC 
and whilst yields were not reported, the purity of the cyclic 
peptoid-peptide hybrids ranged from 77% to 88%, generally 
improving as the sequence got shorter. The authors also 
reported no detectable amounts of the starting linear peptoid-
peptides, or dimerization/oligomerization products.[54a] In 
2016, the same group used this method of cyclisation to 
synthesise a cyclic compound which inhibited Skp2/p300 
interaction, triggering cell apoptosis in cancer cells.[54b] 
This method of cyclisation was later expanded to make 
triazine-bridged bicyclic peptoid-peptide hybrids.55 In this 
system, two cysteine residues were incorporated into the 
sequence, one as the first residue and the second as either 
the fifth, sixth or seventh residue. Once again, the linear 
sequences were capped with cyanuric chloride and 
cyclisation proceeded by incubation of the resin-bound 
peptoid-peptide hybrid with DIPEA in DMF overnight at room 
temperature (Scheme 18). HPLC analysis of the crude 
reaction products showed efficient conversion of the linear 
material to the bicyclic peptoid-peptide hybrids with purities of 
89 – 96% and no detectable by-products.[55] 
 
 
 
 
 
 
 
 
 
 
 
Scheme 18. Synthesis of a triazine-bridged bicyclic peptoid-peptide hybrid. 
4.2 Nucleophilic Substitution 
In 2015, Kaniraj and Maayan reported a high yielding 
side chain-to-tail method of preparing cyclic peptoids. The 
linear parent peptoid includes a chloride side-chain that 
reacts with a secondary amine at the terminus of the peptoid 
chain by substitution under basic conditions (Scheme 19).[56]  
The cyclisation reaction was carried out whilst the 
peptoid was still on resin, meaning that protecting groups on 
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any side-chain functionalities could be removed at the same 
time as the peptoid was cleaved from the resin. This allowed 
for the inclusion of a wide range of functional groups in the 
peptoid chain. Cyclisation was shown to readily occur when 
the propyl chloride side-chain was located in various positions 
on the peptoid chain giving access to ring sizes as small as 4 
and as large as 19.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 19. A general overview of the side-chain-to-tail ring formation 
strategy developed by the Maayan group.  
As previously discussed the Kirshenbaum group have 
pioneered the application of a head-to-tail macrolactamisation 
strategy but macrolactamisation can also be used in a side 
chain-to-tail cyclisation (Scheme 20).[57] However, unlike in 
the head-to-tail approach, the side chain-to-tail method allows 
ring formation to be carried out whilst the peptoid is still on 
the resin. Using this approach Park et al. were able to 
prepare macrocyclic peptoids ranging in ring size from 19 
atomic members to 55 atomic members. The 55 atom peptoid 
macrocycle was, at the time of the work by Park et al. the 
largest peptoid macrocycle reported. Park et al. reported that 
the efficiency of macrolactamisation varied depending on the 
ring size and reaction time (6 – 12 hours). The sequences 
chosen for the peptoids were based on linear and cyclic 
peptide sequences known to inhibit the interaction between 
apolipoprotein E and amyloid-β; a cause of Alzheimer’s 
disease, though whether the cyclic peptoids actually 
interacted with either target was not reported. 
 
 
 
 
Scheme 20. Side chain-to-tail macrolactamisation strategy recently 
reported by Park et al.  
In terms of characterisation, the sequencing of peptoids 
can be problematic. In 2014, the successful sequencing of 
peptoids was achieved by first preparing and cyclising a 
linear peptoid-peptide hybrid on resin (Scheme 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 21. Synthesis of a cyclic peptoid-peptide precursor (34).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22. Cleavage of cyclic peptoid-peptide (34) to give a tagged linear 
peptoid (35). 
A homocysteine was incorporated into the sequence as the 
first residue, giving 31. 32 was then synthesised by the sub-
monomer method and the N-terminus chloroacetylated (33). 
Subsequent deprotection of the homocysteine sulfur 
protecting group and base-mediated cyclisation gave a cyclic 
peptoid-peptide hybrid (34) which, when cleaved from the 
resin, generated a linear peptoid that was tagged at each 
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end. The incorporation of two different end groups enabled 
sequencing by tandem mass spec. The thioether could be 
oxidised by mCPBA to yield the linear peptoid. However, due 
the strong oxidising ability of mCPBA, other functional groups 
in the peptoid were also affected. In order to prevent side 
reactions with other functional groups, the peptoid is 
synthesised on Tentagel S NH2 resin and CNBr can be used 
to cleave the peptoid and open the ring (Scheme 22), giving 
the tagged linear peptoid (35).[58] 
 
4.3 Suzuki Cross-Coupling  
 
The Suzuki reaction represents a versatile method of 
synthesising carbon-carbon bonds. The reaction involves 
palladium-catalysed elimination of a boronic acid and halide 
in the presence of base (Scheme 23).[59] 
 
 
 
 
Scheme 23. The Suzuki cross-coupling reaction. 
Recent work from within our own group has 
demonstrated peptoid cyclisation via an on-resin Suzuki 
cross-coupling reaction (Scheme 24). One of our aims in this 
work was the inclusion of a biaryl linkage within the cyclic 
peptoid, as such motifs are present in many therapeutics 
including antifungal, antitumour, anti-inflammatory and 
antihypertensive agents.[60] In order to achieve this, we had to 
include both an aromatic iodide and an aromatic boronic acid 
in the linear parent peptoid (38) The iodide was incorporated 
by using 3-iodobenzylamine as a building block in sub-
monomer peptoid synthesis. The boronic acids, 3- or 4- 
carboxyphenylboronic acid MIDA ester, were incorporated 
into the linear peptoids using solid-phase peptide synthesis 
conditions (e.g. formation of 38 in Scheme 21). Cyclisation 
was then achieved by incubation of the resin-bound linear 
parent peptoids (e.g. 38) at 80 oC for 8 hours in the presence 
of tetrakis palladium, Buchwald’s ligand (SPhos) and 
potassium carbonate in DMF. Subsequent cleavage from the 
resin and HPLC purification yielded the biaryl-containing 
cyclic peptoids (e.g. 39, Scheme 21) in yields of 3 – 23%.[61]  
Hexameric cyclic biaryl peptoids (39) as well as the larger 
heptameric cyclic biaryl peptoids (e.g. 40) were both 
successfully synthesised. Generally speaking, the cyclisation 
of the longer linear peptoids was less efficient. Biaryl cyclic 
peptoids with 3-3 linkages (e.g. 39 and 40) and 4-4 linkages 
(e.g. 41) were also successfully synthesised. It was found 
that for short linear peptoids the 4-4 regio-isomers cyclised 
more efficiently, whereas with the longer peptoid chains, 
regio-isomerism appeared to make little difference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24. Synthesis of a biaryl-containing macrocylic peptoid (38). 
5. Summary and Outlook 
 
Peptoids represent a promising class of peptidomimetics, 
retaining many of the advantages of peptides, such as 
biocompatibility and a high degree of chemical diversity, 
whilst being far more resistant to proteolytic degradation. 
However, the location of the peptoid side-chains on the 
backbone amide nitrogen precludes any hydrogen bonding 
and as such peptoids display a high degree of conformational 
flexibility. Cyclisation is one approach that the peptoid 
community has adopted in an effort to access peptoids with 
more conformational rigidity. The latter is a highly desirable 
property in the development of therapeutic agents. Since the 
2010 review of this area by Yoo and Kirshenbaum, several 
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new methods of synthesising macrocyclic peptoids have been 
reported, bringing ready access to a new range of peptoid 
scaffolds. The synthesis of macrocyclic peptoids is an area 
that is likely to continue to grow. Molecules of this type offer 
up excellent opportunities for the design of new bioactive 
agents and they can be used as building blocks to access 
complex peptoid nano-structures.  
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